Exact Sciences stock holds steady after Fed-driven market drop
Published on 09/17/2026 at 19:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences stock (ISIN US30063P1057) closed at USD 67.42 on Nasdaq on September 16, 2026, virtually unchanged on the day even as the broader market fell after the latest Federal Reserve rate hike.
Stock shows resilience in a volatile market
According to The Straits Times, the Dow Jones Industrial Average fell 1.21 percent and the S&P 500 lost 0.44 percent on September 16, 2026, while the Nasdaq Composite dipped 0.01 percent as the Fed signaled further tightening ahead.
In that environment, Exact Sciences stock ended the session at USD 67.42 on Nasdaq, with an intraday range between USD 66.91 and USD 68.05 and a trading volume of 1,284,000 shares on September 16, 2026, as reported in a recent price overview.
Recent quarterly figures support Exact Sciences stock
Exact Sciences Corporation, listed on Nasdaq, is best known for its Cologuard colorectal cancer screening test and a broader portfolio of diagnostic products for oncology and other conditions.
In its most recent quarterly report for the second quarter of 2026, Exact Sciences reported revenue of USD 774.0 million, up 12.5 percent from USD 688.0 million in the second quarter of 2025, reflecting continued growth in its core screening and precision oncology businesses.
For that same quarter, the company posted a net loss of USD 42.0 million, an improvement compared with a net loss of USD 68.0 million in the prior-year quarter, as operating leverage and cost discipline helped narrow the deficit.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached USD 96.0 million in the second quarter of 2026, compared with USD 70.0 million a year earlier, showing how scale effects are starting to translate into better underlying profitability.
The second-quarter 2026 report also included guidance for full-year 2026 revenue in a range of USD 3.05 billion to USD 3.15 billion, implying mid-teens percentage growth compared with the USD 2.72 billion recorded in fiscal year 2025.
Analyst views and valuation context
Analyst sentiment toward Exact Sciences stock remains broadly constructive, with several houses highlighting the company's strong position in the colorectal cancer screening market and its expanding precision oncology franchise.
Recent analyst updates have pointed to upside potential relative to the current share price, with price targets in the USD 75 to USD 85 range for the next 12 to 18 months, compared with the USD 67.42 closing level on September 16, 2026.
At that closing price, Exact Sciences commanded a market capitalization of around USD 12.0 billion as of September 16, 2026, placing it firmly in the mid-cap segment of the US healthcare space.
On a price-to-sales basis, the stock traded at roughly 4.0 times the midpoint of the company's 2026 revenue guidance, a valuation that reflects both the growth prospects of its stool-based screening products and the investment needed to expand into additional diagnostic indications.
Risk factors investors are watching
One key risk investors monitor for Exact Sciences stock is reimbursement and policy uncertainty around colorectal cancer screening, as changes in coverage or guidelines could affect test volumes and revenue growth.
Competition is another factor: several large diagnostics and life sciences companies are investing heavily in liquid biopsy and alternative screening technologies, which could gradually pressure pricing or market share in some of Exact Sciences' target segments.
At the same time, the company's ongoing spending on research and development and commercial expansion keeps margins below those of more mature peers, meaning that execution on scaling volumes and controlling costs is crucial to reaching sustained profitability.
Exact Sciences stock price level as of mid-September 2026
As of the last completed trading day on September 16, 2026, Exact Sciences stock closed at USD 67.42 on Nasdaq, with the intraday range between USD 66.91 and USD 68.05 underscoring the relatively tight trading band in spite of the broader market volatility.
Exact Sciences stock key data
- Company: Exact Sciences Corporation
- ISIN: US30063P1057
- Ticker: EXAS
- Trading venue: Nasdaq
- Price (as of September 16, 2026): 67.42 USD
- Market capitalization: 12,000,000,000 USD (as of September 16, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
